SIRT1 and lung carcinoma: The combination of cisplatin and erlotinib with the SIRT1 inhibitor EX527 shown synergistic anticancer effects; however, in lung cancer, EX527-mediated inhibition of SIRT1 increased the efficacy of erlotinib by decreasing cell proliferation, augmenting DNA damage, and increasing apoptosis.